India’s leading biotech firm Biocon on Thursday reported Rs 206-crore consolidated net profit for the first quarter (Q1) of fiscal 2019-20, registering a whopping 86 percent annual growth from Rs 120 crore in the same period a year ago.
In a regulatory filing on the BSE, the city-based firm said consolidated revenue from operations grew 30 percent annually in the quarter under review (Q1) to Rs 1,466 crore from Rs 1,124 crore in the like period a year ago.
Earnings before interest, tax, depreciation, and amortization (Ebitda), also grew 51 percent annually to Rs 462 crore from Rs 307 crore a year ago.
“Robust performance by biologics and small molecules business segments fuelled the growth in the first quarter. Investments in biosimilars are delivering expected results,” said Biocon Chairperson Kiran Mazumdar-Shaw in a statement later here.
The global firm’s net profit was impacted due to an exceptional item on account of tax on group entities restructuring.
“We remain committed to develop quality bio-therapeutics and enable affordable access to patients in world markets,” Shaw said on the occasion.
The drug maker’s research services business continues to provide profitable growth.
Check out your favorite Offers touch the link and read some best Services – Stock Cash Trading Tips || Are u Interested so Contact Here- 9644405057Please follow and like us: